XML 36 R24.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information
Note 16. Segment Information
We operate in one operating segment, and therefore one reportable segment, focused on the global discovery, development and commercialization of proprietary therapeutics. We manage business activities on a consolidated basis through the development and commercialization of oncology and dermatology products, which are sold to U.S. and international customers. Our determination that we operate as a single operating segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods. Our chief operating decision maker is the Chief Executive Officer.
The accounting policies for our single operating segment are the same as those described in the summary of significant accounting policies in our Annual Report on Form 10-K for the year ended December 31, 2024. Our single operating segment generates revenues from the development and commercialization of oncology and dermatology pharmaceutical products, which are developed by our research and development department, as well as from product royalties, milestone and contract revenues from the out-licensing of our intellectual property to third parties.
For our segment, the chief operating decision maker uses net income or loss, that also is reported on the condensed consolidated statements of operations as consolidated net income, to allocate resources (including employees, property, and financial resources), predominantly during the annual budget and forecasting process. The chief operating decision maker also uses consolidated net income or loss, along with non-financial inputs and qualitative information, to evaluate our performance, establish compensation, monitor budget versus actual results, and decide the level of investment in our various operating activities and other capital allocation activities. The measure of segment assets is reported on the condensed consolidated balance sheet as total consolidated assets.
Net income for our segment was as follows (in thousands):
Three Months Ended
March 31,
20252024
Product revenues, net922,274 729,923 
Product royalty revenues130,624 125,966 
Milestone and contract revenues— 25,000 
Total revenues1,052,898 880,889 
Costs, expenses and other:
Cost of product revenues (including definite-lived intangible amortization)73,188 60,956 
Research and development - internal1
228,345 223,096 
Research and development - external2
193,434 205,164 
Other research and development3
15,500 1,000 
Sales and marketing257,652 216,813 
General and administrative68,039 83,443 
Loss (gain) on change in fair value of acquisition-related contingent consideration11,572 (456)
(Profit) and loss sharing under collaboration agreements— (1,025)
Other segment items4
46,965 (77,650)
Net income$158,203 169,548 

1.Research and development - internal is comprised of internally generated costs such as salaries, travel, regulatory costs, lab costs, contracting, etc.
2.Research and development - external is comprised of specific program spend with external vendors (i.e. contract manufacturing organization, contract research organization and lab vendors for clinical, technical operations and toxicology services).
3.Other research and development is comprised of all other costs including certain one-time costs resulting from the acquisition of IPR&D assets and one-time development milestone expenses.
4.Other segment items is comprised of interest income, interest expense, realized and unrealized (gain) loss on equity investments, other, net, and provision for income taxes.
During the three months ended March 31, 2025, total revenues from the United States were approximately $981.6 million, total revenues from Europe were approximately $68.6 million, and total revenues from other countries were approximately $2.7 million. During the three months ended March 31, 2024, total revenues from the United States were approximately $828.2 million, total revenues from Europe were approximately $51.5 million, and total revenues from other countries were approximately $1.2 million.
As of March 31, 2025, property and equipment, net was approximately $469.6 million in the United States, approximately $282.7 million in Switzerland and approximately $13.0 million in other countries. As of December 31, 2024, property and equipment, net was approximately $474.1 million in the United States, approximately $277.6 million in Switzerland and approximately $11.7 million in other countries.